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artery disease requiring revascularization. Sur‑
gical risk assessed with the logistic EuroScore II 
was 7.75%, and with the Society of Thoracic Sur‑
geons score, 3.86%. The Heart Team discussed 
the case and scheduled the patient for transcath‑
eter treatment due to the history of chest radi‑
ation therapy. During the index hospital stay, 
a successful implantation of a self ‑expandable 
Portico 29‑mm valve (Abbott, Santa Clara, Cal‑
ifornia, United States) was performed. Despite 
the successful transcatheter aortic valve implan‑
tation and optimal medical therapy, the patient 
still presented with symptoms of class IV heart 
failure according to the New York Heart Associ‑
ation classification and required invasive ven‑
tilation. The control transesophageal echocar‑
diography confirmed severe MR and TR suitable 
for transcatheter treatment. Four weeks later, 
under general anesthesia, a MitraClip proce‑
dure was performed with 2 NTr clips deployed 
on the mitral leaflets, and a third clip was im‑
planted on the septal and anterior tricuspid 
valve leaflet (Figure 1D–1e). Echocardiography con‑
firmed good hemodynamic results with moder‑
ate MR (MR regurgitant volume, 22 ml; effective 
regurgitant orifice, 0.15 cm2; mean pressure gra‑
dient, 8 mm Hg), (Figure 1F) and mild TR. Despite 
a decrease in left ventricular ejection fraction 
to 40%, a significant increase in stroke volume 
from 40 ml to 70 ml was observed, with a sig‑
nificant reduction of RVSP to 45 mm Hg. These 
values confirmed that a successful MitraClip 
Transcatheter heart valve therapies shed new 
light on effective treatment not only in the el‑
derly but also in patients with concomitant co‑
morbidities such as porcelain aorta or those who 
have undergone chest radiation therapies and 
who are not appropriate candidates for surgery.1 
Transcatheter “edge ‑to ‑edge“ Mitra‑ and Tri ‑Clip 
repair together with transcatheter aortic valve 
implantation have been described as valuable 
therapy options for this subset of patients.2‑4
A 59‑year ‑old man was admitted to our de‑
partment with acute exacerbation of left and 
right ventricular heart failure. His medical his‑
tory included myocardial infarction treated with 
primary percutaneous coronary intervention of 
the right coronary artery, chronic kidney disease 
(stage III), and chemotherapy with subsequent 
chest radiation therapy due to Hodgkin lympho‑
ma. Blood tests revealed a significantly increased 
serum N ‑terminal brain natriuretic peptide lev‑
el of 7232 pg/ml (reference range <125 pg/ml). 
Echocardiography showed a slightly decreased 
left ventricular ejection fraction (48%), severe 
aortic stenosis (aortic valve area, 0.9 cm2; V max, 
3 m/s; mean pressure gradient, 20 mm Hg), se‑
vere mitral regurgitation (MR) type IIIb (based 
on the Carpentier functional classification) (ef‑
fective regurgitant orifice, 0.6 cm2; regurgitant 
volume, 90 ml), and severe tricuspid regurgita‑
tion (TR) with an estimated right ventricular 
systolic pressure (RVSP) of 90 mm Hg (Figure 1A–1C). 
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procedure may lead to RVSP reduction.5 As 
a result, significant clinical improvement was 
achieved, and the patient could be discharged 
home. During 6‑month follow ‑up, echocar‑
diography confirmed a good result of valve in‑
terventions with New York Heart Association 
class II symptoms.
According to the European Society of Cardiol‑
ogy guidelines, surgical treatment for patients 
with defects in multiple valves is the optimal 
choice. However, choosing the optimal meth‑
od, including transcatheter heart valve inter‑
vention, can often be difficult and cannot be 
based only on classic risk scales, as they do not 
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figure 1 A – transthoracic echocardiography, the parasternal long ‑axis view, showing severe calcifications of the aortic valve (arrow); B – transesophageal 
echocardiography, the intercommissural view, showing severe functional mitral regurgitation (arrow); C – transthoracic echocardiography, the 4‑chamber view, 
showing severe tricuspid regurgitation (arrow); D – transesophageal echocardiography, the midesophageal 4‑chamber view, showing released clips during tricuspid 
clip implantation (arrow); E – transesophageal echocardiography, the intercommissural view, showing 2 clips implanted at the A2–P2 segments of the mitral valve, 
mild residual mitral regurgitation (arrow); f – fluoroscopy showing 2 implanted MitraClips, a TriClip, and an aortic valve prosthesis (arrows). The transesophageal 
probe was in the transgastric position.
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